Evidence map›Paper›PMID 31354217›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2019

Impact of crizotinib on long-term survival of

Puyuan Xing, Di Ma, Qiang Wang, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Li Liang, Hongge Liang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Efficacy and safety of crizotinib plus bevacizumab inAmerican journal of translational research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Puyuan XingDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Di MaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Qiang WangDepartment of Pulmonary Medicine (Inpatient Area 1), Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China.
Xuezhi HaoDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Mengzhao WangDepartment of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730, China.
Yan WangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li ShanDepartment of Pulmonary Medicine (Inpatient Area 1), Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China.
Tao XinDepartment of Oncology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Li LiangDepartment of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.
Hongge LiangDepartment of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730, China.
Yang DuDepartment of Oncology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Zhaohui ZhangDepartment of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.
Junling LiDepartment of Pulmonary Medicine (Inpatient Area 1), Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCrizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase (

methodsWe reviewed the medical records of 484 unselected

resultsA total of 428 eligible

conclusionsThis study has demonstrated the clinically meaningful benefit of crizotinib treatment in a large cohort of Chinese

Indexed as

anaplastic lymphoma kinaseCrizotinibnon-small-cell lung cancerreal-world study

Identifiers

PMID31354217
PMCPMC6613511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.